Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
REGULATORY
Chuikyo OKs 7 Drugs Subject to Cost-Effective Review; Re-Pricing to Be Conducted in 2018
A powerful health ministry panel on April 27 agreed to subject seven drugs including Sovaldi (sofosbuvir) and Opdivo (nivolumab) to a pilot-based cost effective assessment scheme, with a plan to carry out re-pricing based on the appraisal results in April…
To read the full story
Related Article
- Chuikyo to Discuss “Price-Setting Including NHI Price Increases” Using Cost-Effective Assessments
December 1, 2016
- Japan Should Adopt French-Type HTA: JMA Exec Suzuki
October 26, 2016
- Chuikyo Member Prods MHLW to Present Data on Savings through Generic Use
April 28, 2016
- Chuikyo OKs Basic Plan for Pilot-Based HTA Scheme; Sovaldi, Opdivo Emerge as Likely Candidates
February 12, 2016
- 4 Listed Drugs plus Similar Products Subject to Cost-Effectiveness Review: Chuikyo
January 21, 2016
- Chuikyo Approves Plan to Introduce Cost-Effective Assessments on Trial Basis; Selection of Products to Begin Next April
December 17, 2015
REGULATORY
- MHLW’s FY2025 Budget Includes 7.7 Billion Yen to Drive Drug Commercialization
January 6, 2025
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
- Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
- LDP Members Urge Ministers to End “Mechanical” Off-Year Price Cuts
December 27, 2024
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…